
Tebentafusp, a gp100xCD3 bispecific ImmTAC, induces rash as an off-tumor, on-target effect by recruiting T cells to melanocytes in the skin. Rash development is linked to baseline gp100 expression. Despite this, rash occurrence does not impact overall survival.
Like
Save
Share